Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MBC-11 is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC). It also has the potential to treat tumor-induced bone disease (TIBD).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | MBC-11 is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC). It also has the potential to treat tumor-induced bone disease (TIBD). |
In vitro | MBC-11 reduces KAS-6/1 cell growth from approximately 56% at 10-8 M to 6% at 10-5 M. MBC-11 displays similar activity profiles and obviously suppresses the growth of all three cell lines between 10-8 and 10-4 M [1]. |
In vivo | MBC-11 obviously reduces bone tumor burden compared to PBS- or zoledronate-treated mice. MBC-11 (0.04 μg/day, s.c.) has a lower incidence of bone metastases of 40% compared to those treated with PBS (90%) or 0.04 μg/day zoledronate (100%). Weight gained in mice treated with up to 500 μg/day of MBC-11 is similar to the PBS treated group. These results show that MBC-11 decreases bone tumor burden maintains the bone structure, and may increase overall survival, warranting further investigation as a treatment for tumor-induced bone disease (TIBD)[1]. |
Molecular Weight | 511.21 |
Formula | C11H20N3O14P3 |
CAS No. | 332863-86-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MBC-11 332863-86-2 Others MBC11 MBC 11 inhibitor inhibit